相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cholinergic control of striatal neurons to modulate L-dopa-induced dyskinesias
Tanuja Bordia et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2019)
Distinct Dopamine D2 Receptor Antagonists Differentially Impact D2 Receptor Oligomerization
Elise Wouters et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Luminescence- and Fluorescence-Based Complementation Assays to Screen for GPCR Oligomerization: Current State of the Art
Elise Wouters et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Revealing Adenosine A(2A)-Dopamine D-2 Receptor Heteromers in Parkinson's Disease Post-Mortem Brain through a New AlphaScreen-Based Assay
Victor Fernandez-Duenas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Effects of Muscarinic Acetylcholine m1 and m4 Receptor Blockade on Dyskinesia in the Hemi-Parkinsonian Rat
Nicole E. Chambers et al.
NEUROSCIENCE (2019)
Heterodimerization of Mu Opioid Receptor Protomer with Dopamine D2 Receptor Modulates Agonist-Induced Internalization of Mu Opioid Receptor
Lakshmi Vasudevan et al.
BIOMOLECULES (2019)
Behavioral control by striatal adenosine A2A-dopamine D2 receptor heteromers
J. Taura et al.
GENES BRAIN AND BEHAVIOR (2018)
International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease
Susan H. Fox et al.
MOVEMENT DISORDERS (2018)
Activation of Dopamine D1-D2 Receptor Complex Attenuates Cocaine Reward and Reinstatement of Cocaine-Seeking through Inhibition of DARPP-32, ERK, and Delta FosB
Ahmed Hasbi et al.
FRONTIERS IN PHARMACOLOGY (2018)
Essential Control of the Function of the Striatopallidal Neuron by Pre-coupled Complexes of Adenosine A2A-Dopamine D2 Receptor Heterotetramers and Adenylyl Cyclase
Sergi Ferre et al.
FRONTIERS IN PHARMACOLOGY (2018)
Neurochemical evidence supporting dopamine D1-D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulation
Alberto J. Rico et al.
BRAIN STRUCTURE & FUNCTION (2017)
M1 muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons
Xiaohui Lv et al.
NEUROPHARMACOLOGY (2017)
Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder
Caio M. Massari et al.
FRONTIERS IN PHARMACOLOGY (2017)
Striatal Neurons Expressing D1 and D2 Receptors are Morphologically Distinct and Differently Affected by Dopamine Denervation in Mice
D. Gagnon et al.
SCIENTIFIC REPORTS (2017)
Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay
Annelies Cannaert et al.
ANALYTICAL CHEMISTRY (2016)
Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease
Samira Ztaou et al.
JOURNAL OF NEUROSCIENCE (2016)
Commentary: Evaluation of Models of Parkinson's Disease
Pollyana C. Leal et al.
FRONTIERS IN NEUROSCIENCE (2016)
Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model
Anderson H. F. F. Leao et al.
BRAIN PATHOLOGY (2015)
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia
Weixing Shen et al.
NEURON (2015)
Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats
Victor Fernandez-Duenas et al.
DISEASE MODELS & MECHANISMS (2015)
Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes
Dasiel O. Borroto-Escuela et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
L-DOPA-treatment in primates disrupts the expression of A2A adenosine-CB1 cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus
Jordi Bonaventura et al.
NEUROPHARMACOLOGY (2014)
Parkinson disease: from pathology to molecular disease mechanisms
David T. Dexter et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
Review: management of Parkinson's disease
David J Pedrosa et al.
Neuropsychiatric Disease and Treatment (2013)
Effect of enhanced Renilla luciferase and fluorescent protein variants on the Forster distance of Bioluminescence resonance energy transfer (BRET)
Helen Dacres et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Extrasynaptic neurotransmission in the modulation of brain function. Focus on the striatal neuronal-glial networks
Kjell Fuxe et al.
FRONTIERS IN PHYSIOLOGY (2012)
BRET and Time-resolved FRET strategy to study GPCR oligomerization: from cell lines toward native tissues
Martin Cottet et al.
Frontiers in Endocrinology (2012)
Roles of the M1 Muscarinic Acetylcholine Receptor Subtype in the Regulation of Basal Ganglia Function and Implications for the Treatment of Parkinson's Disease
Zixiu Xiang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum
Pierre Trifilieff et al.
BIOTECHNIQUES (2011)
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease
Susan Duty et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson's Disease
Susan H. Fox et al.
MOVEMENT DISORDERS (2011)
Hetero-dimerization of serotonin 5-HT2A and dopamine D2 receptors
Sylwia Lukasiewicz et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2010)
The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats
Martin Weber et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2010)
Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules
Jonathan A. Hern et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells
Nuria Cabello et al.
JOURNAL OF NEUROCHEMISTRY (2009)
A Novel Selective Muscarinic Acetylcholine Receptor Subtype 1 Antagonist Reduces Seizures without Impairing Hippocampus-Dependent Learning
Douglas J. Sheffler et al.
MOLECULAR PHARMACOLOGY (2009)
Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers.: A combined neurochemical and behavioral analysis
Daniel Marcellino et al.
NEUROPHARMACOLOGY (2008)
Pharmacotherapy for Parkinson's disease
Jack J. Chen et al.
PHARMACOTHERAPY (2007)
Re-emergence of striatal cholinergic interneurons in movement disorders
Antonio Pisani et al.
TRENDS IN NEUROSCIENCES (2007)
D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons
D. James Surmeier et al.
TRENDS IN NEUROSCIENCES (2007)
A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease
Carlos Singer et al.
MOVEMENT DISORDERS (2007)
Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease
Paolo Barone et al.
MOVEMENT DISORDERS (2007)
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Juergen Wess et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Quantitative analysis of muscarinic acetylcholine receptor homo- and heterodimerization in live cells - Regulation of receptor down-regulation by heterodimerization
JC Goin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Sumanirole, a highly dopamine D2-selective receptor agonist:: In vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease
RB McCall et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys
DT Stephenson et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Alternatives to levodopa in the initial treatment of early Parkinson's disease
A Lees
DRUGS & AGING (2005)
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease
P Jenner
CURRENT OPINION IN NEUROLOGY (2003)
Selective cognitive dysfunction in acetylcholine M-1 muscarinic receptor mutant mice
SG Anagnostaras et al.
NATURE NEUROSCIENCE (2003)
Muscarinic induction of hippocampal gamma oscillations requires coupling of the M1 receptor to two mixed cation currents
A Fisahn et al.
NEURON (2002)
Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice
DJ Gerber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor
T Miyakawa et al.
JOURNAL OF NEUROSCIENCE (2001)
Coordinated expression of muscarinic receptor messenger RNAs in striatal medium spiny neurons
Z Yan et al.
NEUROSCIENCE (2001)
Cholinergic neuronal modulation alters dopamine D2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover:: Positron emission tomography studies with microdialysis in the conscious monkey brain
H Tsukada et al.
JOURNAL OF NEUROSCIENCE (2000)
Effects of the selective M1 muscarinic receptor antagonist dicyclomine on emotional memory
RV Fornari et al.
LEARNING & MEMORY (2000)
Acetylcholine-mediated modulation of striatal function
P Calabresi et al.
TRENDS IN NEUROSCIENCES (2000)
分享论文
